Company Overview

Financial Performance Highlights

Standalone Performance (₹ in Crores)

  • Total Income: ₹880.56 crore (FY25: ₹604.07 crore) - 45.9% growth
  • EBITDA: ₹102.25 crore (FY25: ₹90.82 crore)
  • EBITDA Margin: 11.61% (FY25: 15.03%)
  • Profit Before Tax: ₹67.86 crore (FY25: ₹57.77 crore)
  • Profit After Tax: ₹50.30 crore (FY25: ₹42.27 crore) - 19% growth
  • Earnings Per Share: ₹11.52 (FY25: ₹9.68)

Consolidated Performance (₹ in Crores)

  • Total Income: ₹880.79 crore (FY25: ₹601.59 crore)
  • Profit After Tax: ₹44.49 crore (FY25: ₹38.69 crore)

Key Financial Ratios

  • Current Ratio: 2.19 times (FY25: 2.68 times)
  • Debt Equity Ratio: 0.23 times (FY25: 0.11 times)
  • Return on Net Worth: 10.18% (FY25: 9.68%)
  • Inventory Turnover: 13.73 times (FY25: 9.16 times)
  • Interest Coverage Ratio: 19.14 times (FY25: 20.41 times)

Segment Performance

Chemical Business

  • Revenue ₹829.56 crore (FY25: ₹504.31 crore), EBIT ₹69.26 crore
  • Plant utilization at 95-97% throughout the year
  • Expanded H-Acid manufacturing capacity from 400 to 500 metric tons per month
  • Expected incremental revenue of ₹50-75 crore annually from expanded capacity
  • Commenced plasticizers production at Tarapur facility in December 2025
  • Strong export demand from Southeast Asia and Europe

Solar Energy Business

  • Revenue ₹26.86 crore (FY25: ₹27.83 crore), EBIT ₹11.57 crore
  • Subsidiary Rahuri Cleantech commissioned 21 MW solar capacity
  • Part of larger 32 MW capacity build-out under Maharashtra's MSKVY 2.0 scheme
  • Long-term power purchase agreements with SECI for 25 years

Pharmaceutical Business

  • Revenue ₹4.20 crore (FY25: ₹8.12 crore), EBIT loss of ₹5.49 crore
  • Continuing R&D investments in Vitamins and Steroids API categories
  • Focus on building regulatory infrastructure and global healthcare supply chain understanding

Dividend Declaration

  • Recommended final dividend of ₹2.50 per equity share (50% of face value)
  • Dividend payout ratio: 21.69% of profits
  • Record date: July 24, 2026
  • Payment date: On or before August 31, 2026, subject to shareholder approval

Corporate Actions

37th Annual General Meeting

  • Date: August 1, 2026
  • Time: 12:30 PM
  • Mode: Video Conferencing/Other Audio Visual Means

Agenda Items

Ordinary Business:

1. Adoption of audited standalone and consolidated financial statements

2. Declaration of dividend

3. Re-appointment of Mr. Vikas Bhageria who retires by rotation

Special Business:

4. Re-appointment of Mr. Suresh Bhageria as Executive Director & Chairman for 3 years

5. Re-appointment of Mr. Vinod Bhageria as Managing Director for 3 years

6. Re-appointment of Mr. Vikas Bhageria as Joint Managing Director for 3 years

Foreign Exchange & Exports

  • Foreign Exchange Earned: ₹30,371.92 lakh (FY25: ₹9,109.94 lakh) - 227% growth
  • Foreign Exchange Outgo: ₹9,294.18 lakh (FY25: ₹9,295.99 lakh)
  • Export contribution: 35.8% of total revenue

Subsidiaries & Corporate Structure

  • Bhageria & Jajodia Pharmaceuticals Private Limited (51% holding)
  • Rahuri Cleantech Private Limited (100%)
  • Salasar Renewables Private Limited (100%)
  • Hikaru Solar Power Private Limited (100%)
  • New Ahilyanagar Solar Private Limited (100%)
  • Bhageria Industries Holding Company W.L.L. (liquidated November 20, 2025)

Regulatory Compliance & Audit

  • Statutory Auditors: Sarda & Pareek LLP, Chartered Accountants
  • Audit Fees: ₹8.75 lakhs
  • No material significant orders passed by regulators or courts
  • No proceedings under Insolvency and Bankruptcy Code, 2016
  • Company confirms compliance with all applicable Secretarial Standards

Credit Ratings

  • Long-term Bank Facilities: CARE A; Stable/ CARE A1
  • Short-term Bank Facilities: CARE A Stable/ CARE A1
  • Some facilities under rating watch with negative implications